Asunto(s)
Anticuerpos Monoclonales/administración & dosificación , Antineoplásicos/administración & dosificación , Linfoma de Células B de la Zona Marginal/tratamiento farmacológico , Neoplasias de los Músculos/tratamiento farmacológico , Músculos Oculomotores , Anticuerpos Monoclonales de Origen Murino , Humanos , Linfoma de Células B de la Zona Marginal/patología , Masculino , Persona de Mediana Edad , Neoplasias de los Músculos/patología , Músculos Oculomotores/patología , Inducción de Remisión , Rituximab , Neoplasias Gástricas/tratamiento farmacológico , Neoplasias Gástricas/patología , Factores de TiempoAsunto(s)
Neoplasias Óseas/patología , Paraproteinemias/patología , Plasmacitoma/patología , Neoplasias Pleurales/patología , Neoplasias Retroperitoneales/patología , Anciano , Neoplasias Óseas/sangre , Neoplasias Óseas/tratamiento farmacológico , Resultado Fatal , Humanos , Masculino , Paraproteinemias/sangre , Paraproteinemias/tratamiento farmacológico , Plasmacitoma/sangre , Plasmacitoma/tratamiento farmacológico , Neoplasias Pleurales/sangre , Neoplasias Pleurales/tratamiento farmacológico , Neoplasias Retroperitoneales/sangre , Neoplasias Retroperitoneales/tratamiento farmacológicoAsunto(s)
Mielofibrosis Primaria/tratamiento farmacológico , Corticoesteroides/uso terapéutico , Preescolar , Quimioterapia Combinada , Eritropoyetina/uso terapéutico , Femenino , Humanos , Lactante , Masculino , Mielofibrosis Primaria/complicaciones , Mielofibrosis Primaria/etiología , Inducción de Remisión/métodos , Talidomida/uso terapéutico , Resultado del TratamientoRESUMEN
INTRODUCTION: The purpose of our study was to evaluate the effectiveness and safety of combined therapy with deferoxamine (DFO) and deferiprone (DFP) in patients with beta-thalassemia major and increased serum ferritin. PATIENTS AND METHODS: Our study was performed in 36 patients with beta-thalassemia major. DFP was administered orally in a total daily dose of 60 mg/kg for 6 days per week and DFO was administered subcutaneously in a total daily dose of 40-50 mg/kg for 4-6 days per week. The efficacy of combined treatment was assessed by measurements of serum ferritin and 24-h urine iron excretion levels. RESULTS: Out of the 36 patients, 11 discontinued DFO after a mean of 4 months; however, 25 patients, who continued to receive the combined therapy showed a very satisfactory compliance. After a mean of 13.5 months, their mean serum ferritin levels reduced from 2637 + 1292 to 1580 + 1024 ng/ml (P = 0.002) and their mean urinary iron excretion elevated from 0.41 + 0.27 to 0.76 +0.49 mg/24h (P = 0.003). The observed side effects were gastrointestinal disorders,elevations in liver enzymes, mild neutropenia, joint symptoms, taste disorders, dizziness and fatigue. CONCLUSIONS: The results of this study show that combined iron-chelation therapy with DFO and DFP results in satisfactory reduction of serum ferritin with no significant toxicity.